Cargando…

Evaluation of the effect of favipiravir on patients with COVID-19

BACKGROUND: The novel coronavirus disease 2019 caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV2) started in December 2019 in Wuhan, China. No specific drug has been accepted for COVID-19 treatment up to now. Favipiravir as an antiviral drug affects RNA viruses like influenza and...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kamali, Alireza, Sarmadian, Hossein, Mahmoodiyeh, Behnam, Valibeik, Shamim, Farmani, Farzane, Bashirgonbadi, Zahra
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Wolters Kluwer - Medknow 2023
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10114572/ https://www.ncbi.nlm.nih.gov/pubmed/37091030 http://dx.doi.org/10.4103/jfmpc.jfmpc_1058_22

Ejemplares similares

Guillain–Barré syndrome following COVID‐19 vaccine: A case report
por: Fakhari, Mohammad Sadegh, et al.
Publicado: (2022)

Favipiravir for COVID-19 in a Patient on Hemodialysis
por: Hirai, Daisuke, et al.
Publicado: (2021)

Population pharmacokinetics of favipiravir in patients with COVID‐19
por: Irie, Kei, et al.
Publicado: (2021)

Hematological Malignancy Patients, COVID-19, and Favipiravir
por: Mungmunpuntipantip, Rujittika, et al.
Publicado: (2021)

Favipiravir Effects on the Control of Clinical Symptoms of Hospitalized COVID-19 Cases: An Experience with Iranian Formulated Dosage Form
por: Tabarsi, Payam, et al.
Publicado: (2021)

Effectiveness of Early Favipiravir Therapy in Hospitalised COVID-19 Patients
por: Tawfik, Abdulrahman, et al.
Publicado: (2022)

A Single-Centered Cohort Study on Favipiravir Safety and Efficacy in Pediatric Patients with COVID-19
por: Rafiei Tabatabaei, Sedigheh, et al.
Publicado: (2022)

Role of favipiravir in the treatment of COVID-19
por: Joshi, Shashank, et al.
Publicado: (2021)

Effect of favipiravir and an anti-inflammatory strategy for COVID-19
por: Yamamura, Hitoshi, et al.
Publicado: (2020)

Pharmacokinetics of Favipiravir in Critically Ill Patients With COVID‐19
por: Irie, Kei, et al.
Publicado: (2020)

Favipiravir exposure and pregnancy outcome of COVID-19 patients
por: Tırmıkçıoğlu, Zeynep
Publicado: (2022)

Use of Favipiravir in Lactating Mother With COVID-19
por: Karabayır, Nalan, et al.
Publicado: (2021)

Future of antivirals in COVID-19: The case of favipiravir
por: Kow, Chia Siang, et al.
Publicado: (2022)

Post‐COVID‐19 splenic infarction in a patient with chronic atrial fibrillation: A case report
por: Sarmadian, Roham, et al.
Publicado: (2022)

Comparing ICU admission rates of mild/moderate COVID-19 patients treated with hydroxychloroquine, favipiravir, and hydroxychloroquine plus favipiravir
por: Guner, Rahmet, et al.
Publicado: (2021)

Effectiveness of favipiravir in COVID-19: a live systematic review
por: Özlüşen, Batu, et al.
Publicado: (2021)

Evaluation of risk factors for uric acid elevation in COVID-19 patients treated with favipiravir
por: Hanai, Yuki, et al.
Publicado: (2022)

Favipiravir and hyperuricemia in patients with COVID-19—suggestions for future studies
por: Kow, Chia Siang, et al.
Publicado: (2023)

A Favipiravir-induced Fever in a Patient with COVID-19
por: Kurita, Takashi, et al.
Publicado: (2020)

Favipiravir Experience in Covid-19 Positive Myasthenia Gravis Patients
por: Yevgi, Recep, et al.
Publicado: (2021)

Clinical efficacy and safety of favipiravir in the treatment of COVID-19 patients
por: Chen, Ping-Jen, et al.
Publicado: (2021)

PIONEER trial: favipiravir to treat moderate COVID-19
por: Shalhoub, Sarah
Publicado: (2023)

Favipiravir and the Need for Early Ambulatory Treatment of COVID-19
por: Korman, Tony M.
Publicado: (2021)

SARS-CoV-2 Viral Shedding and Associated Factors among COVID-19 Inpatients and Outpatients
por: Sofian, Masoomeh, et al.
Publicado: (2022)

Adverse effects associated with favipiravir in patients with COVID-19 pneumonia: a retrospective study
por: Ergür, Figen Öztürk, et al.
Publicado: (2022)

Severe sinus bradycardia associated with favipiravir in a COVID‐19 patient
por: Habib, Mhd Baraa, et al.
Publicado: (2021)

Effect of Inhaled Colistin on the Treatment of Ventilator-Associated Pneumonia due to Multi-drug Resistant Acinetobacter
por: Moradi Moghaddam, Omid, et al.
Publicado: (2019)

Combined Therapy of Ciclosporin Plus Favipiravir in the Management of Patients with Severe COVID-19, not Responding to Dexamethasone: A non-Controlled Prospective Trial
por: Barati, Saghar, et al.
Publicado: (2021)

Regional trends in the use of steroids and favipiravir for COVID-19 treatment
por: Asai, Yusuke, et al.
Publicado: (2023)

Favipiravir: A new and emerging antiviral option in COVID-19
por: Agrawal, Umang, et al.
Publicado: (2020)

Understanding the pharmacokinetics of Favipiravir: Implications for treatment of influenza and COVID-19
por: Ison, Michael G., et al.
Publicado: (2021)

An economical and practical procedure of favipiravir synthesis for the treatment of Covid-19
por: Karatas, Hacer, et al.
Publicado: (2022)

Comparison of three interventional approaches to prevent ventilator-associated pneumonia in intensive care units (ICUs): A clinical trial study
por: Zarinfar, Nader, et al.
Publicado: (2021)

Efficacy of ketamine, propofol, and dexmedetomidine for anesthesia in electroconvulsive therapy in treatment-resistant major depressive disorder patients: a double-blind randomized clinical trial
por: Modir, Hesameddin, et al.
Publicado: (2022)

Adverse events associated with nafamostat mesylate and favipiravir treatment in COVID-19 patients
por: Hifumi, Toru, et al.
Publicado: (2020)

Suspected cholestatic liver injury induced by favipiravir in a patient with COVID-19
por: Yamazaki, Shingo, et al.
Publicado: (2021)

Favipiravir-Induced Drug Fever in a Young Adult COVID-19 Patient
por: Jadeja, Dhigishaba M, et al.
Publicado: (2021)

Favipiravir‐induced nephrotoxicity in a patient with COVID‐19: A case report
por: Abdelbary, Asmaa A., et al.
Publicado: (2021)

Drug Fever Due to Favipiravir Administration for the Treatment of a COVID-19 Patient
por: Tawara, Junsuke, et al.
Publicado: (2021)

Favipiravir for the treatment of patients with COVID-19: a systematic review and meta-analysis
por: Manabe, Toshie, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_ris494jgocu2khd91l5ejgq1lt